Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2026)

Indivior Pharmaceuticals' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $296.0 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 6.09% year-over-year to $296.0 million in Q1 2026; TTM through Mar 2026 was $296.0 million, a 6.09% increase from a year earlier, with the FY2025 full-year figure at $323.0 million, up 16.61% from the prior year.
• Long-Term Deferred Tax slipped to $296.0 million in Q1 2026 per INDV's latest filing, from $323.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $323.0 million in Q4 2025 and bottomed at $219.0 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $282.0 million (2025), against an average of $279.4 million.
• Across the five-year window, Long-Term Deferred Tax jumped 108.57% in 2022 and decreased 3.15% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $219.0 million in 2022, then jumped by 30.59% to $286.0 million in 2023, then fell by 3.15% to $277.0 million in 2024, then climbed by 16.61% to $323.0 million in 2025, then retreated by 8.36% to $296.0 million in 2026.
• Per Business Quant, the three latest INDV Long-Term Deferred Tax figures stand at $296.0 million (Q1 2026), $323.0 million (Q4 2025), and $285.0 million (Q3 2025).